Clin Mol Hepatol.
2024 Oct;30(4):714-717. 10.3350/cmh.2024.0425.
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Stanford University Medical School, Stanford, CA, USA
- KMID: 2560078
- DOI: http://doi.org/10.3350/cmh.2024.0425
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
- Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma
- The Metformin Use and Gastric Cancer Risk
- Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
